Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity

Launched by OUI THERAPEUTICS, INC. · Jun 6, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new digital program designed to help adults who struggle with binge eating and obesity. The main goal is to see if this online tool can effectively support people dealing with both of these challenges. The study is not yet recruiting participants, but it aims to involve adults between the ages of 18 and 70 who speak English, have experienced binge eating at least 12 times in the last three months, and have a body mass index (BMI) of 30 or higher, which is considered obese. Participants will need to have an iPhone or an Android phone that meets specific software requirements.

If you qualify and decide to participate, you can expect to learn more about how to manage your eating habits through this digital program. It's important to know that the trial is not open to everyone. For instance, individuals with certain mental health issues or those who are currently enrolled in other treatment studies will not be eligible. Overall, this trial represents an innovative approach to addressing binge eating and obesity, and your involvement could help researchers understand its effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. English speaking male or female patients, 18-70 years
• • 2. Patients with recurrent binge eating (≥12 episodes in 3 months) and obesity (BMI ≥30)
• • 3. Understand written and spoken English
• • 4. Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher
• • 5. Willing and able to complete enrollment procedures
• • 6. Able to understand the nature of the study and provide written informed consent
• Exclusion Criteria:
• • 1. Patients with active psychosis
• • 2. Patients who are acutely intoxicated at the time of enrollment
• • 3. Currently enrolled in other treatment studies for the symptoms and behaviors targeted
• • 4. Patients who are cognitively impaired
• • 5. Patients who, in the judgment of the investigator, would have an unfavorable risk/benefit profile with respect to the digital therapeutic